Trial reportAsia-Pacific journal of clinical oncology2026
Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open-Label, Single-Arm, Phase IV Study.
Trial report in Asia-Pacific journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open-Label, Single-Arm, Phase IV Study.Asia-Pacific journal of clinical oncology · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
introductionTrastuzumab emtansine (T-DM1), an antibody-drug conjugate, targets tumor cells overexpressing human epidermal growth factor receptor 2 (HER2). This single-arm, phase IV study assessed the safety and efficacy of T-DM1 in Indian patients with HER2-positive, locally advanced, or metastatic breast cancer previously treated with trastuzumab and a taxane.
methodsPatients received T-DM1 (3.6 mg/kg intravenously every 3 weeks) until death, disease progression, unacceptable toxicity, consent withdrawal, or up to a maximum of 12 months after the last patient's first visit, whichever occurred first. Safety was mainly assessed by the incidence and severity of adverse events (AEs). Efficacy was evaluated by progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). Patients were followed up posttreatment until 12 months or until lost to follow-up, withdrawn consent, or death.
resultsA total of 70 eligible patients (median age [range]: 50.0 [27.0-75.0] years) received at least one dose of T-DM1 (median duration [range]: 32.0 [1.0-125.0] weeks). Adverse events in 21 (30.0%) patients were treatment-related. The most common treatment-related AEs and SAEs were thrombocytopenia (seven [10.0%] and three [4.0%] patients, respectively) and epistaxis (four [6.0%] and two [3.0%] patients, respectively). During the study, 10 (18.0%) patients died (disease progression: n = 6; AE: n = 3; and unknown reason: n = 1), while 2 patients died during the follow-up period. Median PFS was 14 months (95% confidence interval [CI]: 8.0, 17.0). Among 65 evaluable patients, 16 (23.0%) achieved partial responses; ORR was 23.0%.
conclusionsTrastuzumab emtansine was found to be safe and efficacious in the Indian patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.